Introduction
The amyloid ␤-protein (A␤) is strongly implicated in the cognitive decline of Alzheimer's disease (AD) (Selkoe, 2002) , and great effort has been expended in characterizing the most pathogenically important A␤ assemblies (Shankar and Walsh, 2009 ). Water-soluble nonfibrillar assemblies of A␤ have been found to be highly toxic to synapses, providing a basis for the positive correlation between disease severity and postmortem concentration of soluble A␤ (Lue et al., 1999; McLean et al., 1999; Wang et al., 1999) . The concentration of water-soluble A␤ oligomers, in particular SDS-stable A␤ dimers, is elevated in the brains of AD patients (Mc Donald et al., 2010) and aqueous extracts of AD brain that contain such dimers powerfully inhibit long-term potentiation (LTP) in mouse hippocampal slices and impair avoidance learning in rats (Shankar et al., 2008) . Several putative receptor sites have been proposed to mediate disruptive effects of A␤ on synaptic plasticity including proteoglycans (Snow et al., 1995) ; receptor for advanced glycation end products (Yan et al., 2009) ; LRP (Deane et al., 2004) ; integrins (Wright et al., 2007) ; and nicotinic (Wang et al., 2000) , NMDA (Bi et al., 2002) , insulin (Xie et al., 2002) , and p75 neurotrophin (Yaar et al., 1997) receptors. The selectivity of these sites in mediating the disruptive effects as opposed to putative physiological roles of A␤ (Puzzo et al., 2008; Giuffrida et al., 2010 ) is unclear.
Recently, a broad range of different sized A␤ assemblies termed A␤-derived diffusible ligands (ADDLs), but not A␤ monomers, were discovered to bind with high affinity to cellular prion protein (PrP c ), specifically in a region that encompassed the amino acid sequence 95-105 (Laurén et al., 2009) . Moreover, blocking PrP c with an antibody recognizing this region or a genetic knockout of PrP c prevented the inhibition of LTP by ADDLs in hippocampal slices. Although the potent and selective binding of PrP C by ADDLs has been confirmed (Balducci et al., 2010; Chen et al., 2010) , whether or not such binding mediates their synaptic plasticity-disrupting actions is controversial. Recently, Kessels et al. (2010) failed to replicate the finding that the inhibition of LTP by ADDLs was absent in slices from Prnp Ϫ/Ϫ mice. Furthermore, an impairment of synaptic plasticity in hippocampal slices from APPPS1 ϩ transgenic mice was not significantly affected when this strain of mice was crossed with Prnp Ϫ/Ϫ mice (Calella et al., 2010) . Given the potential clinical implications of a causative role for the binding of A␤ oligomers to PrP C in neuronal dysfunction (Kellett and Hooper, 2009) and the controversy over the mechanisms of the effects of synthetic and transgenic mouse-generated A␤, we tested the involvement of PrP C in mediating in vivo synaptic plasticity disruption by the most disease-relevant preparation of A␤, human brain-derived soluble A␤ (Shankar et al., 2008 ). Here we report that the inhibition of LTP by human brain extract containing SDS-stable dimers was prevented using an an-tibody fragment (Fab) directed to the 96 -104, but not the 225-231, region of PrP C (Williamson et al., 1998) in the rat in vivo. These findings strongly support the potential value of immunotherapeutically targeting the binding of synaptotoxic A␤ assemblies to PrP C .
Materials and Methods
In vivo LTP. Experiments were performed on urethane (1.5 g/kg, i.p.)-anesthetized male Wistar rats (250 -300 g) under the approval of the ethical review committee of Trinity College Dublin and the Department of Health and Children, Ireland. The electrophysiological methods have been described previously (Klyubin et al., 2008) . Briefly, twisted-wire, bipolar, Teflon-coated tungsten wires (62.5 m inner core diameter, 75 m external diameter) served as stimulation electrodes. Field EPSPs were recorded from the stratum radiatum in the CA1 area in response to stimulation of the Schaffer collateral-commissural pathway. Recording electrodes were located 3.4 mm posterior to bregma and 2.5 mm right of midline, and the stimulating electrode was located 4.2 mm posterior to bregma and 3.8 right of midline. The depth of the electrodes was optimized using electrophysiological criteria. Test EPSPs were evoked at a frequency of 0.033 Hz and at a stimulation intensity adjusted to elicit an EPSP amplitude of 50% of maximum. The high-frequency stimulation (HFS) protocol for inducing LTP consisted of 10 trains of 20 stimuli with an interstimulus interval of 5 ms (200 Hz) and an intertrain interval of 2 s, and the intensity was increased to evoke an EPSP of 75% of maximum amplitude. Samples were injected through a stainless steel guide cannula (22 gauge, 0.7 mm outer diameter, 13 mm length) that was implanted above the right lateral ventricle (1 mm lateral to the midline and 4 mm below the surface of the dura). Unless otherwise stated, two sequential intracerebroventricular injections were administered (5 l of human brain extract 30 min after 10 l of Fab in PBS or equivalent volumes of distilled water or PBS vehicle) via an internal cannula (28 gauge, 0.36 mm outer diameter).
Preparation and analysis of aqueous extracts of human brain. Human brain tissue was obtained and used in accordance with the University College Dublin Human Research Ethics Committee guidelines (under Approval LS-E-10 -10-Walsh). All three AD cases (a 75-year-old woman, an 80-year-old woman, and an 85-year-old man) were demented before death, and had fulminant amyloid and tangle pathology. A fourth brain was from a cognitively intact 90-year-old woman and lacked any significant AD pathology. Frozen samples of frontal or temporal cortex (1 g) were allowed to thaw on ice, chopped into small pieces with a razor blade, and then homogenized in 5 ml of ice-cold 20 mM Tris, pH 7.4, containing 150 mM NaCl (TBS) with 25 strokes of a Dounce homogenizer (Fisher). To separate water-soluble A␤ from membrane-bound or plaque A␤, homogenates were centrifuged at 91,000 ϫ g and 4°C in a TLA 55 rotor (Beckman-Coulter) for 78 min. To eliminate bioactive small molecules and drugs, the supernatant was exchanged into ammonium acetate using a 5 ml Hi-trap desalting column (GE Healthcare Bio-Sciences AB). Thereafter, the extract was divided into three parts: one aliquot was immunodepleted of A␤ by three rounds of 12 h incubation with the anti-A␤ antibody AW8 and protein A at 4°C. The second portion (the "mock immunodepletion") was subjected to the same procedure as used with the first sample, but preimmune AW8 sera were used instead of AW8 antiserum. The third aliquot was not manipulated in any way. Aliquots of samples were stored at Ϫ80°C or were used to assess A␤ content using a sensitive immunoprecipitation/Western blotting procedure (Mc Donald et al., 2010) . Briefly, samples were immunoprecipitated with AW8 at a dilution 1:80 and analyzed by Western blotting using a combination of the C-terminal monoclonal antibodies 2G3 and 21F12, each at a concentration of 1 g/ml (kind gifts from Dr. Peter Seubert, Elan Pharmaceuticals). Immunoreactive bands were visualized using a fluorochrome coupled secondary antibody (Rockland) and were quantified by comparison to synthetic A␤ standards (Keck laboratory, Yale University, New Haven, CT) using a Licor Odyssey imaging system (Licor Biosciences).
Statistics. LTP is expressed as the mean Ϯ SEM percentage baseline field EPSP amplitude recorded over at least a 30 min baseline period. Statistical comparisons used ANOVA with post hoc Tukey test or paired and unpaired Student's t tests, as appropriate. MannWhitney U tests were used to analyze changes in baseline synaptic transmission.
Results

Human AD brain A␤ selectively inhibits LTP
The TBS-soluble extract of the cerebral cortex from AD patients used in the present studies contained readily detectible A␤, which included SDS-stable dimer consistent with our previous findings (Mc Donald et al., 2010) (Fig. 1 A) .
Acute intracerebroventricular injection of the soluble A␤ from AD brain (5 l) 15 min before the application of highfrequency (200 Hz) conditioning stimulation strongly inhibited LTP. Thus, in control, vehicle-injected, rats LTP magnitude measured 135 Ϯ 7% pre-HFS baseline at 3 h (n ϭ 5, p Ͻ 0.05 compared with pre-HFS baseline), whereas in rats injected with the soluble A␤-containing AD brain supernatant (69 pg of A␤1-42 equivalent) LTP was completely inhibited (103 Ϯ 5%; n ϭ 5; p Ͼ 0.05 compared with pre-HFS baseline; p Ͻ 0.05 compared with vehicle) (Fig. 1 B) . Strong evidence that the A␤ was responsible for the inhibition of LTP was provided by the finding that TBS samples of the same brain extract treated with a polyclonal antibody, AW8, which immunodepleted A␤ (Fig. 1A) , failed to inhibit LTP after intracerebroventricular (5 l) injection (139 Ϯ 8%; n ϭ 4; p Ͻ 0.05 compared with pre-HFS baseline and nonimmunodepleted extract; p Ͼ 0.05 compared with vehicle) (Fig. 1C) . Similar inhibition of LTP by A␤-containing brain TBS extracts from two other AD patients (101 Ϯ 6%; n ϭ 5; p Ͼ 0.05 compared with pre-HFS baseline; p Ͻ 0.05 compared with vehicle) (Figs. 2, 3A) , was also abrogated by immunodepletion of A␤ with AW8 [131 Ϯ 6% (n ϭ 5) and 139 Ϯ 8% (n ϭ 4), respectively; p Ͻ 0.05 compared with pre-HFS baseline and nonimmunodepleted extract; p Ͼ 0.05 compared with vehicle; data not shown]. Because the process of A␤ immunodepletion may remove other potentially important factors, we also tested TBS samples of AD brain extract that had been treated with preimmune serum. Such mockimmunodepleted extract still contained abundant SDS-stable A␤ dimer (38 pg of A␤1-42 equivalent) (Fig. 1 A) and strongly inhibited LTP (103 Ϯ 6%, n ϭ 4; p Ͻ 0.05 compared with vehicle-injected controls and animals injected with A␤-immunodepleted samples) (Fig. 1C) .
The disruption of synaptic function by the A␤-containing supernatant was selective for LTP over baseline synaptic transmission since injection of the dose of A␤ that completely inhibited LTP did not significantly affect baseline EPSPs (103 Ϯ 2% at 3 h postinjection; n ϭ 4; p Ͼ 0.05 compared with preinjection baseline or compared with 102 Ϯ 2%, n ϭ 4, in vehicle-injected rats) (Fig. 1 D) . Similarly immunodepleted aqueous brain extract did not significantly affect baseline synaptic transmission (102 Ϯ 2%; n ϭ 4; p Ͼ 0.05 compared with preinjection baseline or with vehicle-injected rats).
Importantly, samples of an equivalent TBS extract from the brain of a nondemented control subject, did not contain detectible amounts of soluble A␤ (data not shown) and failed to inhibit LTP (Fig. 2) . Thus, HFS induced robust LTP in animals injected (5 l, i.c.v.) with the control human brain TBS extract (136 Ϯ 9%, n ϭ 4, p Ͻ 0.05 compared with pre-HFS baseline; 133 Ϯ 5% n ϭ 8, p Ͼ 0.05 compared with vehicle).
PrP
C dependence of human AD brain A␤-mediated inhibition of LTP Next we investigated the requirement for PrP C , in particular the putative ADDL binding sequence spanning residues 95-105 (Laurén et al., 2009; Chen et al., 2010) , in the ability of A␤-containing AD brain-soluble extract to inhibit LTP. We pretreated animals with the recombinant monovalent antigen-binding Fab fragment D13, which has a high affinity for an epitope 96 -104 of PrP C (Williamson et al., 1998) . We also studied the effects of the Fab fragment R1, which binds with high affinity to an epitope encompassing amino acids 225-231 (Williamson et al., 1998) , which is located at the C-terminus region of PrP C and therefore distal to the putative binding sites for ADDLs (Laurén et al., 2009; Chen et al., 2010) .
Injection of water-soluble, A␤-containing AD brain extract (583 pg of A␤1-42 equivalent in 5 l) 15 min before HFS completely inhibited LTP measured at 3 h (101 Ϯ 4%, n ϭ 6, p Ͼ 0.05 compared with pre-HFS baseline; p Ͻ 0.05 compared with 131 Ϯ 2%, n ϭ 13, in animals that received two injections, 10 l followed 15 min later with 5 l, of vehicle) (Fig. 3A) . Similarly, the A␤-containing AD brain extract also completely inhibited LTP in animals preinjected with the PrP C 225-231 -binding Fab R1 (11 g) (107 Ϯ 6, n ϭ 5; p Ͼ 0.05 compared with baseline; p Ͻ 0.05 compared with vehicle injections) (Fig. 3B) . In marked contrast, preinjection of the PrP C 96 -104 -binding Fab, D13 (11 g in 10 l) fully abrogated the inhibition of LTP by the human brain extract. Thus, HFS induced robust LTP (128 Ϯ 2%, n ϭ 5; p Ͻ 0.05 compared with baseline; p Ͼ 0.05 compared with vehicle-injected controls) in animals administered the A␤-containing extract 30 min after intracerebroventricular injection of D13 (Fig. 3B) . Importantly, neither D13 (11 g) nor the control Fab R1 (11 g) injected before immunodepleted AD brain extract (5 l) significantly affected LTP (136 Ϯ 7, n ϭ 5, and 145 Ϯ 9%, n ϭ 4, respectively; p Ͻ 0.05 compared with baseline; p Ͼ 0.05 compared with 139 Ϯ 8% in vehicle-injected controls n ϭ 5) (Fig. 3C) at the dose used to investigate the role of PrP C in mediating the disruption of synaptic plasticity by A␤-containing AD extract.
Discussion
The present findings strongly support and extend the proposal that the potent and selective disruption of synaptic plasticity by soluble A␤ assemblies is mediated through PrP C . Whereas previous research had focused on the effects of synthetic A␤ assemblies in the mouse in vitro, we provide convincing in vivo evidence in the rat that PrP C is necessary for the inhibition of LTP of hippocampal synaptic transmission by A␤-containing AD brain extract. Moreover, consistent with a key role of a direct interaction of A␤ with the putative binding site in the 95-105 region of PrP C , we report that blocking PrP C 96 -104 , but not the C terminus of PrP C was effective in preventing the inhibition of LTP. Aqueous buffer-soluble extract of the cerebral cortex from AD patients that contained readily detectible SDS-stable dimer powerfully disrupted synaptic plasticity in vivo, consistent with our previous in vitro findings (Shankar et al., 2008) . In these and the present studies, immunodepletion of A␤ effectively abrogated the inhibition of LTP, providing strong evidence for a critical role of A␤. Here we found further support for this conclusion by the ability of mock-immunodepleted samples to fully inhibit LTP. Similar to our previous in vitro studies (Shankar et al., 2008) , equivalent extract from the cortex of a non-AD control subject did not contain such soluble A␤ and did not inhibit LTP in vivo. The present findings are also consistent with our previous report that SDS-stable A␤ dimer-containing CSF from living human volunteers inhibited LTP in vivo, whereas samples that only contained detectible monomer were inactive (Klyubin et al., 2008) .
The finding that PrP C is necessary for the inhibition of LTP in vivo by A␤-containing AD brain TBS extract is consistent with the discovery that soluble synthetic A␤ assemblies bind with high affinity to PrP C to trigger disruption of synaptic plasticity in vitro (Laurén et al., 2009 ). However, Kessels et al. (2010) reported that synthetic A␤ oligomers strongly inhibited LTP in hippocampal slices from Prnp Ϫ/Ϫ mice. This conflict underlines a major difficulty with preparing equivalent preparations of synthetic A␤ oligomers. Synthetic A␤ preparations vary greatly in their composition even when great care is taken to follow rigid protocols to produce specific assemblies (Hepler et al., 2006) . Unlike the synthetic A␤ oligomer preparation used by Kessels et al. (2010) , which also caused a marked reduction in baseline excitatory synaptic transmission, the A␤-containing AD brain extract selectively inhibited LTP in vivo. Indeed, the vast majority of previous reports found that considerably higher concentrations of synthetic A␤ are necessary to significantly reduce baseline excitatory synaptic transmission under the same conditions both in vivo and in vitro (Cullen et al., 1997; Shankar and Walsh, 2009) , and it is likely that such higher levels act via additional sites, bypassing the need for an interaction with PrP C . Also in apparent conflict with the present findings and those of Laurén et al. (2009) , in hippocampal slices from 4-month-old APPPS1ϩ mice crossed with Prnp Ϫ/Ϫ mice LTP was impaired to the same extent as in slices from age-matched pure APPPS1ϩ mice. However, at this age there is already extensive deposition of A␤ in plaques in the brain of this strain of mice (Grathwohl et al., 2009) , and it is uncertain whether A␤ oligomers play a role in the observed impairment of synaptic plasticity seen in such mice.
That D13, an antibody fragment that binds PrP C 96 -104 , prevented the inhibition of LTP by soluble AD brain extract, whereas R1, an antibody fragment that binds the C terminus of PrP C , failed to significantly alter the inhibition, points to the key role of the ADDL-binding sequence in PrP C (amino acids 95-105) identified by Laurén et al. (2009) . Indeed, Laurén et al. (2009) found that a polyclonal antibody to the C-terminal part of PrP C failed to affect ADDL binding to cultured cells, whereas two antibodies to the region shared with D13 prevented binding. Chen et al. (2010) confirmed the importance of this region of PrP C but also found evidence that the N terminus of PrP C may act as an ancillary binding site for ADDLs. Laurén et al. (2009) found that PrP C accounted for ϳ50% of high-affinity binding sites on cultured hippocampal neuron cell membranes, which has been confirmed by Renner et al. (2010) . Thus, in their open screen Laurén et al. (2009) reported that other sites included APLP1, and Renner et al. (2010) provided indirect evidence that PrP C binding by A␤ oligomers was colocalized with both mGlu5 (glutamate metabotropic subtype 5) and NMDA receptors. In the latter case, A␤ oligomer binding caused the accumulation of A␤ at synapses and aberrant changes in the membrane distribution of glutamate receptors. It was suggested [225] [226] [227] [228] [229] [230] [231] . Preinjection with D13 (11 g in 10 l, n ϭ 5) prevented the inhibition of LTP by the brain extract. In contrast, the brain extract completely inhibited LTP in animals pretreated with R1 (11 g, n ϭ 5). C, Neither D13 nor R1 significantly affected control LTP. Preinjection with D13 (n ϭ 5) or R1 (n ϭ 4) before injection of A␤-immunodepleted AD brain TBS extract did not significantly affect LTP compared with animals that received two injections of vehicle (n ϭ 5). Insets show representative traces at the times indicated. Calibration: 1.5 mV, 10 ms.
that A␤ oligomers can act as an extracellular scaffold promoting the cross-linking of glutamate receptors and leading to disruption of synapses apparently by the formation of ectopic signaling platforms at the plasma membrane (Renner et al., 2010) . Interestingly, PrP C is found in lipid raft-like domains of the plasma membranes, as are glutamate receptors (Francesconi et al., 2009; Kellett and Hooper, 2009; Delint-Ramirez et al., 2010) , and aggregation of A␤ oligomers in such regions has been strongly implicated in mediating neurotoxicity (Zampagni et al., 2010) .
How the present findings implicating PrP C in the synaptic plasticity-disrupting actions of A␤ in vivo relate to behavioral and cognitive changes remain to be determined. Intriguingly, crossing APP transgenic mice (APPPSde9) with Prnp Ϫ/Ϫ-null mice abrogated A␤-associated spatial memory deficits (Gimbel et al., 2010) , and systemic treatment with the anti-PrP C antibody 6D11 rapidly reversed impairment of radial maze learning in these mice (Chung et al., 2010) . However, a rapid A␤-mediated disruption of object recognition learning was not apparently reduced in Prnp Ϫ/Ϫ mice (Balducci et al., 2010) , making it important to determine whether cognitive impairment caused by human brain-derived soluble A␤ is dependent on PrP C .
